BRIEF-Puma Biotechnology Inc submits MAA for neratinib
June 27, 2016 at 09:06 AM EDT
* Puma biotechnology submits marketing authorization application (MAA) for PB272 (neratinib) as extended adjuvant treatment of her2-positive early stage breast cancer in europe
